By Tyler Durden With shares already reflecting a post-COVID dearth of revenue streams, Pfizer’s growth outlook just took another hit as it halted development of its…
July 16, 2024
By Tyler Durden With shares already reflecting a post-COVID dearth of revenue streams, Pfizer’s growth outlook just took another hit as it halted development of its…